Position in JNJ
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$3,678,065,449
+$1,044,444,387 QoQ
Shares Held
15,046,905
+18.2% QoQ
Ownership
0.625%
of shares outstanding
% of Portfolio
0.59%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 93.755646094662.ToString("F0")%
None 6.2443539053380075.ToString("F0")%
Common Shares in JNJ Over Time
Shares Held
Position Value (USD)
Derivatives in JNJ
reported options exposure · as of Dec 31, 2020CallValue
$424,926
CallShares
2,700
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026Invesco Ltd. holds $19,373,328,434 across 15 Drug Manufacturers - General names. JNJ ranks #1 (19.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
This page
|
15,046,905 | $3,678,065,449 | |
| 2 | LLY |
ELI LILLY & Co
|
3,454,585 | $3,177,423,634 | |
| 3 | MRK |
Merck & Co., Inc.
|
21,855,101 | $2,628,950,086 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
15,526,336 | $2,163,905,435 | |
| 5 | AZN |
Astrazeneca PLC
|
10,103,749 | $1,992,661,366 | |
| 6 | ABBV |
AbbVie Inc.
|
7,798,048 | $1,695,997,449 | |
| 7 | AMGN |
Amgen Inc
|
4,571,725 | $1,608,561,432 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
15,509,999 | $940,681,432 |
All Filings in JNJ
Export CSV
29 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,678,065,449 | 15,046,905 | Shares | Defined | 2026-05-12 | |
| 2025-12-31 | $2,633,621,062 | 12,725,881 | Shares | Defined | 2026-02-19 | |
| 2025-09-30 | $2,524,351,442 | 13,614,235 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $2,141,089,868 | 14,016,955 | Shares | Defined | 2025-08-13 | |
| 2025-03-31 | $3,063,845,234 | 18,474,706 | Shares | Defined | 2025-05-12 | |
| 2024-12-31 | $2,766,013,536 | 19,126,079 | Shares | Defined | 2025-02-13 | |
| 2024-09-30 | $2,909,642,081 | 17,954,104 | Shares | Defined | 2024-11-12 | |
| 2024-06-30 | $2,434,926,055 | 16,659,319 | Shares | Defined | 2024-08-13 | |
| 2024-03-31 | $2,256,977,870 | 14,267,513 | Shares | Defined | 2024-05-14 | |
| 2023-12-31 | $2,081,847,002 | 13,282,168 | Shares | Defined | 2024-02-13 | |
| 2023-09-30 | $1,944,900,703 | 12,487,324 | Shares | Sole | 2023-11-13 | |
| 2023-06-30 | $2,275,012,637 | 13,744,639 | Shares | Defined | 2023-08-11 | |
| 2023-03-31 | $2,154,756,990 | 13,901,658 | Shares | Defined | 2023-05-12 | |
| 2022-12-31 | $2,229,115,779 | 12,618,827 | Shares | Defined | 2023-02-13 | |
| 2022-09-30 | $2,190,714,927 | 13,410,351 | Shares | Defined | 2022-11-14 | |
| 2022-06-30 | $2,374,498,362 | 13,376,702 | Shares | Defined | 2022-08-15 | |
| 2022-03-31 | $2,244,892,112 | 12,666,547 | Shares | Defined | 2022-05-16 | |
| 2021-12-31 | $2,142,824,522 | 12,526,010 | Shares | Defined | 2022-02-14 | |
| 2021-09-30 | $1,859,490,646 | 11,513,874 | Shares | Defined | 2021-11-15 | |
| 2021-06-30 | $1,702,574,383 | 10,334,918 | Shares | Sole | 2021-08-17 | |
| 2021-03-31 | $1,694,520,312 | 10,310,437 | Shares | Sole | 2021-05-17 | |
| 2020-12-31 | $424,926 | 2,700 | Call | Defined | 2021-02-16 | |
| 2020-12-31 | $1,604,637,189 | 10,195,941 | Shares | Sole | 2021-02-16 | |
| 2020-09-30 | $1,719,194,324 | 11,547,517 | Shares | Sole | 2020-11-16 | |
| 2020-09-30 | $401,976 | 2,700 | Call | Defined | 2020-11-16 | |
| 2020-06-30 | $393,764 | 2,800 | Call | Defined | 2020-08-14 | |
| 2020-06-30 | $1,746,540,073 | 12,419,399 | Shares | Sole | 2020-08-14 | |
| 2020-03-31 | $367,164 | 2,800 | Call | Defined | 2020-05-15 | |
| 2020-03-31 | $1,683,766,891 | 12,840,440 | Shares | Sole | 2020-05-15 | |
| No filing history on record for this holder in this stock. | ||||||